News Release

Lilly supports the administration’s goal of keeping the United States the world’s leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries. This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US.

Medicine prices should reflect their value for patients, health systems, and society. In recent months, we have intensified efforts to align prices across developed countries, especially in Europe. We are continuing to work with certain governments and expect to make any necessary pricing adjustments by September 1, while providing continued access for patients. This includes an agreement with the UK government to increase the list price of Mounjaro, while maintaining access for NHS patients.

In the U.S., we have taken concrete steps to lower patient costs: scaling Lilly Direct to provide more affordable access to Lilly medicines, including Zepbound, and leading the industry by reducing insulin prices by 70% and capping what people pay monthly at $35.

While we agree that the costs for breakthrough medicines should be more fairly shared across developed countries, we must also address the underlying structural issues in the U.S. that have contributed to high drug prices. The U.S. system is complex and opaque, with multiple cross subsidies, abuse of government programs like 340B, and insurance cost-sharing burdens for patients. This makes the U.S. different from other developed nations, which have a less complicated system and low, or no out-of-pocket costs for patients.

Since 2020, Lilly has committed over $50 billion to U.S. manufacturing expansion, including 10 active projects designed to supply the U.S. market entirely from U.S. facilities and increase exports. We have also announced $5 billion to expand capacity in other countries.

Lilly opposes tariffs on pharmaceutical products, including on the medicines we make. Medicines have long been excluded from tariffs because of their life‑saving nature. Broad tariffs would raise costs, limit patient access, and undermine American leadership, especially for companies already investing heavily in domestic manufacturing. We urge the administration and Congress to prioritize strategic incentives that strengthen U.S. manufacturing and supply‑chain resilience without sacrificing access, affordability, innovation, or American leadership.

Lilly remains committed to working with the administration on drug‑pricing reforms that benefit patients and sustains America’s leadership in biomedical innovation.

###